alexa Abstract | Effect of Tenofovir/Emtricitabine/Efavirenz with and without Chloroquine in Patients with HIV/AIDS C3: Double Blinded Randomized Clinical Trial
ISSN: 2329-6887

Journal of Pharmacovigilance
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Background: The use of antiretroviral therapy (ART) reduces both mortality and morbidity of patients with HIV/ AIDS. The effects of chloroquine against HIV replication are widely known.

Objective: To demonstrate that beginning HIV treatment with ART (tenofovir/emtricitabine/efavirenz) + chloroquine increases by at least 20% the proportion of patients with viral load (VL) <50 copies/mL and >200 CD4+/mcL compared to patients receiving only ART at six months follow up.

Method: A randomized double-blind clinical trial was performed in 95 patients at the Infectious Diseases Department of the Hospital General de Mexico diagnosed with HIV/AIDS classification C3 before their first ART: 48 patients in the ART + placebo group and 47 in the ART + chloroquine group.

Results: A difference of 37% at six months of treatment in advantage of the group of ART + chloroquine (p<0.001), and seven times greater chance of improvement using chloroquine in the first six months of treatment. Chloroquine decreased the frequency of IRIS in 20%, compared with the group that initiated ART only at six months follow-up with statistical difference (p=0.029).

Conclusion: Chloroquine can improve the immune response and decrease the frequency of inflammatory syndrome by immune reconstitution at six months if added to the initial ART with tenofovir/emtricitabine/efavirenz.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Banda-Lara Marco Isaac, Martínez-García María del Carmen, Vázquez-Rosales José Guillermo, Rendón-Macías Mario Enrique, Flores-Hernández Sergio, Rivera-Benítez César, Santos-González Margarito and Carrillo-Avalos Blanca Ariadna


Adverse Effects, Medication Error

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version